Kate Giuliano Verdi

All Publications

• Repair of giant pulmonary artery aneurysm and quadricuspid pulmonic valve with valve-sparing pulmonic root replacement. JTCVS techniques Verdi, K. G., Feng, I., Zhou, A. L., Woo, Y. J. 2025; 30: 69-72

  View details for DOI 10.1016/j.xjtc.2024.12.004

  View details for PubMedID 40242102

  View details for PubMedCentralID PMC11998398

• Repair of giant pulmonary artery aneurysm and quadricuspid pulmonic valve with valve-sparing pulmonic root replacement JTCVS TECHNIQUES Verdi, K., Feng, I., Zhou, A. L., Woo, Y. 2025; 30: 69-72

  View details for DOI 10.1016/j.xjtc.2024.12.004

  View details for Web of Science ID 001461129700001

• Resequenced Ross pulmonary autograft procedure: Novel approach with beating heart predominance to minimize cross-clamp and cardiopulmonary bypass times JTCVS TECHNIQUES Farag, J. A., Verdi, K. G., Weininger, G., Woo, Y. 2025; 30: 43-45

  View details for DOI 10.1016/j.xjtc.2024.11.015

  View details for Web of Science ID 001460785000001

• Resequenced Ross pulmonary autograft procedure: Novel approach with beating heart predominance to minimize cross-clamp and cardiopulmonary bypass times. JTCVS techniques Farag, J. A., Verdi, K. G., Weininger, G., Woo, Y. J. 2025; 30: 43-45

  View details for DOI 10.1016/j.xjtc.2024.11.015

  View details for PubMedID 40242093

  View details for PubMedCentralID PMC11998392

• Surgical repair of aneurysmal left circumflex coronary artery fistula to coronary sinus. JTCVS techniques Shi, M., Verdi, K. G., Woo, Y. J. 2025; 29: 77-81

  View details for DOI 10.1016/j.xjtc.2024.11.010

  View details for PubMedID 39991280

  View details for PubMedCentralID PMC11845396

• Mitral valve repair of papillary muscle rupture using multi-neochord reconstruction JTCVS TECHNIQUES Zhou, A. L., Feng, I., Verdi, K. G., Liou, K., Woo, Y. 2025; 29: 23-26

  View details for DOI 10.1016/j.xjtc.2024.10.018

  View details for Web of Science ID 001418858400001

• Mitral valve repair of papillary muscle rupture using multi-neochord reconstruction. JTCVS techniques Zhou, A. L., Feng, I., Verdi, K. G., Liou, K., Woo, Y. J. 2025; 29: 23-26

  View details for DOI 10.1016/j.xjtc.2024.10.018

  View details for PubMedID 39991279

  View details for PubMedCentralID PMC11845380

• Ross procedure following prior unroofing of anomalous coronary artery, pulmonary arteriopexy, and three aortic valve repair operations JTCVS TECHNIQUES Verdi, K., Woo, Y. 2024; 28: 35-38

  View details for DOI 10.1016/j.xjtc.2024.09.007

  View details for Web of Science ID 001368985700001

• Ross procedure following prior unroofing of anomalous coronary artery, pulmonary arteriopexy, and three aortic valve repair operations. JTCVS techniques Verdi, K. G., Woo, Y. J. 2024; 28: 35-38

  View details for DOI 10.1016/j.xjtc.2024.09.007

  View details for PubMedID 39669361

  View details for PubMedCentralID PMC11632344

• Racial disparities among patients on venovenous extracorporeal membrane oxygenation in the pre- Coronavirus Disease 2019 and Coronavirus Disease 2019 eras: A retrospective registry review JTCVS OPEN Enumah, Z., Etchill, E. W., Kim, B., Giuliano, K. A., Kalra, A., Cho, S., Whitman, G. J. R., Ha, J. S., Choi, C., Higgins, R. S. D., Bush, E. L. 2024; 17: 162-171

  Abstract

  Although many studies have addressed such disparities caused by COVID-19, to our knowledge, no study has focused on the association of race on outcomes for patients with COVID-19 requiring venovenous extracorporeal membrane oxygenation support. The goal of this study was to assess association of race on death and duration on venovenous extracorporeal membrane oxygenation in both the pre-COVID-19 and COVID-19 eras.We retrospectively reviewed the Extracorporeal Life Support Organization registry and included adults (≥18 years) who required venovenous extracorporeal membrane oxygenation between January 2019 and April 2021. We performed descriptive statistics and multivariable logistic regression. Our primary outcomes were death and extracorporeal membrane oxygenation duration.A total of 7477 patients were included after excluding 340 patients (4.3%) who were missing race data. In the COVID-19 era, 1474 of 2777 COVID-19-positive patients (53.1%) died. Our regression model suggested somewhat of a protective effect on death for Black and multiple race patients. Additionally, a diagnosis of COVID-19 and patients in the COVID-19 era in general, irrespective of COVID-19 diagnosis, had higher odds of death. Hispanic patients had the longest average venovenous extracorporeal membrane oxygenation run times.Our study using data from the international Extracorporeal Life Support Organization Registry provides updated data on patients supported with venovenous extracorporeal membrane oxygenation in the pre-COVID-19 and COVID-19 eras between 2019 and 2021 with a focus on race. Patients in the COVID-19 era group also had higher mortality compared with those in the pre-COVID-19 era even after being adjusted for COVID-19 diagnosis. Black and multiple races appeared somewhat protective in terms of death. Hispanic race was associated with longer venovenous extracorporeal membrane oxygenation duration.

  View details for DOI 10.1016/j.xjon.2023.12.008

  View details for Web of Science ID 001314428300001

  View details for PubMedID 38420563

  View details for PubMedCentralID PMC10897667

• Automatic 1-year follow-up appointment creation and reminders can improve long-term follow-up after carotid revascularization AMERICAN JOURNAL OF SURGERY Stonko, D. P., Mohammed, S., Skojec, D., Rutkowski, J., Call, D., Verdi, K. G., Tsai, L. L., Black III, J. H., Perler, B. A., Abularrage, C. J., Lum, Y., Salameh, M. J., Hicks, C. W. 2024; 227: 57-62

  Abstract

  Long-term follow-up (LTFU) following carotid revascularization is important for post-surgical care, stroke risk optimization and post-market surveillance of new technologies.We instituted a quality improvement project to improve LTFU rates for carotid revascularizations (primary outcome) by scheduling perioperative and one-year follow-up appointments at time of surgery discharge. A temporal trends analysis (Q1 2019 through Q1 2022), multivariable regression, and interrupted time series (ITS) were performed to compare pre-post intervention LTFU rates.269 consecutive patients were included (151 pre-intervention, 118 post-intervention; mean 71 ​± ​12 years-old, 39% female, 77% White). The overall LTFU rate improved (64.9%-78.8%; P ​= ​0.013) after the intervention. After controlling for patient factors, procedures performed after the intervention were associated with increased odds of being seen for 1-year follow-up (OR: 2.2 95%CI: 1.2-4.0). Quarterly ITS analysis corroborated this relationship (P ​= ​0.01).Time-of-surgery appointment creation and automated patient reminders can improve LTFU rates following carotid revascularizations.

  View details for DOI 10.1016/j.amjsurg.2023.09.032

  View details for Web of Science ID 001135677700001

  View details for PubMedID 37827870

  View details for PubMedCentralID PMC10797636

• Lung Transplantation in Patients With COVID-19-The Early National Experience Florissi, I. S., Etchill, E. W., Barbur, I., Verdi, K. G., Merlo, C., Bush, E. L. ELSEVIER INC. 2023: 822-830

  Abstract

  Lung transplant (LT) has become a viable option for COVID-19 patients suffering from end-stage Acute Respiratory Distress Syndrome (ARDS). This analysis sought to describe the early national experience of COVID-19 patients who received LT and compare transplant characteristics and short-term outcomes of COVID-19 and non-COVID-19 ARDS LT recipients. We queried the Organ Procurement and Transplantation database for adults (≥18 years old) receiving LT from January 2009 to March 31, 2022 with diagnoses of COVID-19 or ARDS. We identified 353 COVID-19 and 64 non-COVID-19 ARDS LT recipients. COVID-19 recipients were older (median age: 51, interquartile range [40-57] years vs 41 [26-52]; P < 0.001), more predominantly male (78% (n = 274) vs 55% (n = 35), P < 0.001), and had higher body mass indices (median 27.2 interquartile range [24.5-30.9] vs 25.4 [22.1-28.6]; P < 0.01) than non-COVID-19 ARDS recipients. COVID-19 LT recipients were less frequently reliant on extra-corporeal membrane oxygenation at 72 hours after transplant (26% (n = 80) vs 31% (n = 15), P < 0.001), and were less frequently dependent on dialysis post-transplant than non-COVID-19 ARDS LT recipients (14% (n = 43) vs 23% (n = 14); P = 0.01). Survival at 90 days post-transplant was comparable for the non-COVID ARDS (90%, n = 54) and COVID-19 (94%, n = 202) LT recipients with available follow-up (P = 0.17). LT appears to be a viable therapy for COVID-19 patients with end-stage lung disease. COVID-19 LT and non-COVID-19 ARDS LT recipients have comparable 90 days post-transplant survival.

  View details for DOI 10.1053/j.semtcvs.2022.08.008

  View details for Web of Science ID 001127793400001

  View details for PubMedID 36038079

  View details for PubMedCentralID PMC9420205

• Ketamine Mitigates Neurobehavioral Deficits in a Canine Model of Hypothermic Circulatory Arrest Giuliano, K., Etchill, E., Velez, A. K., Wilson, M., Blue, M. E., Troncoso, J. C., Baumgartner, W. A., Lawton, J. S. ELSEVIER INC. 2023: 251-258

  Abstract

  Hypothermic circulatory arrest is a protective technique used when complete cessation of circulation is required during cardiac surgery. Prior efforts to decrease neurologic injury with the NMDA receptor antagonist MK801 were limited by unacceptable side effects. We hypothesized that ketamine would provide neuroprotection without dose-limiting side effects. Canines were peripherally cannulated for cardiopulmonary bypass, cooled to 18°C, and underwent 90 minutes of circulatory arrest. Ketamine-treated canines (n = 5; total dose 2.85 mg/kg) were compared to untreated controls (n = 10). A validated neurobehavioral deficit score was obtained at 24, 48, and 72 hours (0 = no deficits/normal exam; higher score represents increasing deficits). Biomarkers of neuronal injury in the cerebrospinal fluid were examined at baseline and at 8, 24, 48, and 72 hours. Brain histopathologic injury was scored at 72 hours (higher score indicates more necrosis and apoptosis). Ketamine-treated canines had significantly improved, lower neurobehavioral deficit scores compared to controls (overall P = 0.003; 24 hours: median 72 vs 112, P = 0.030; 48 hours: 47 vs 90, P = 0.021; 72 hours: 30 vs 89, P = 0.069). Although the histopathologic injury scores of ketamine-treated canines (median 12) were lower than controls (16), there was no statistical difference (P = 0.10). Levels of phosphorylated neurofilament-H and neuron specific enolase, markers of neuronal injury, were significantly lower in ketamine-treated animals (P = 0.010 and = 0.039, respectively). Ketamine significantly reduced neurologic deficits and biomarkers of injury in canines after hypothermic circulatory arrest. Ketamine represents a safe and approved medication that may be useful as a pharmacologic neuroprotectant during cardiac surgery with circulatory arrest.

  View details for DOI 10.1053/j.semtcvs.2021.12.004

  View details for Web of Science ID 001025284900001

  View details for PubMedID 34995752

  View details for PubMedCentralID PMC9253200

• Heart Allocation Change and Multiple Temporary Circulatory Support as Bridge-to-Bridge JOURNAL OF SURGICAL RESEARCH Barbur, I., Etchill, E. W., Giuliano, K., McGoldrick, M. T., Jager, L., Whitman, G., Kilic, A. 2023; 285: 35-44

  Abstract

  We investigated how the 2018 Organ Procurement and Transplantation Network heart allocation policy change was associated with changes in characteristics and outcomes of candidates receiving multiple temporary mechanical circulatory support (mtMCS) devices.We included adult heart transplant candidates listed October 2014-January 2018 and October 2018-January 2022 in the United Network of Organ Sharing dataset. Prepolicy and postpolicy mtMCS recipients were compared at listing, transplant, 90-days, and 1-year post-transplant. Time between first and second devices and time between first device and transplant were modeled via multivariable linear regression. Transplantation likelihood was modeled using competing risks analysis.Postpolicy, a higher proportion of transplant candidates received mtMCS (4% versus 1%, P < 0.001), and received their second device an adjusted 49 d sooner versus prepolicy (P = 0.001). Time to transplant was also an adjusted 35 d shorter postpolicy, with an 80% increased transplantation likelihood versus prepolicy (95% confidence interval: 1.6-1.9, P < 0.001). Postpolicy patients experienced reduced waitlist mortality (8% versus 14%, P = 0.04) with marked improvements in 90-day (93% versus 85%, P < 0.001) and 1-year (88% versus 70%, P = 0.01) post-transplant survival.Postpolicy mtMCS recipients are more likely to progress to transplantation sooner on the waitlist and their shorter waitlist course together with earlier change to a secondary device was associated with improved post-transplant survival versus prepolicy.

  View details for DOI 10.1016/j.jss.2022.12.021

  View details for Web of Science ID 000993753200001

  View details for PubMedID 36640608

• ATP-Sensitive Potassium Channel Opener Diazoxide Reduces Myocardial Stunning in a Porcine Regional With Subsequent Global Ischemia Model Velez, A. K., Etchill, E., Giuliano, K., Kearney, S., Jones, M., Wang, J., Cho, B., Brady, M., Dodd-o, J., Meyer, J. M., Lawton, J. S. WILEY. 2022: e026304

  Abstract

  Background ATP-sensitive potassium channels are inhibited by ATP and open during metabolic stress, providing endogenous myocardial protection. Pharmacologic opening of ATP potassium channels with diazoxide preserves myocardial function following prolonged global ischemia, making it an ideal candidate for use during cardiac surgery. We hypothesized that diazoxide would reduce myocardial stunning after regional ischemia with subsequent prolonged global ischemia, similar to the clinical situation of myocardial ischemia at the time of revascularization. Methods and Results Swine underwent left anterior descending occlusion (30 minutes), followed by 120 minutes global ischemia protected with hyperkalemic cardioplegia±diazoxide (N=6 each), every 20 minutes cardioplegia, then 60 minutes reperfusion. Cardiac output, time to wean from cardiopulmonary bypass, left ventricular (LV) function, caspase-3, and infarct size were compared. Six animals in the diazoxide group separated from bypass by 30 minutes, whereas only 4 animals in the cardioplegia group separated. Diazoxide was associated with shorter but not significant time to wean from bypass (17.5 versus 27.0 minutes; P=0.13), higher, but not significant, cardiac output during reperfusion (2.9 versus 1.5 L/min at 30 minutes; P=0.05), and significantly higher left ventricular ejection fraction at 30 minutes (42.5 versus 15.8%; P<0.01). Linear mixed regression modeling demonstrated greater left ventricular developed pressure (P<0.01) and maximum change in ventricular pressure during isovolumetric contraction (P<0.01) in the diazoxide group at 30 minutes of reperfusion. Conclusions Diazoxide reduces myocardial stunning and facilitates separation from cardiopulmonary bypass in a model that mimics the clinical setting of ongoing myocardial ischemia before revascularization. Diazoxide has the potential to reduce myocardial stunning in the clinical setting.

  View details for DOI 10.1161/JAHA.122.026304

  View details for Web of Science ID 000893866000020

  View details for PubMedID 36444837

  View details for PubMedCentralID PMC9851454

• Arterial Carbon Dioxide and Acute Brain Injury in Venoarterial Extracorporeal Membrane Oxygenation ASAIO JOURNAL Shou, B. L. L., Ong, C., Zhou, A. L., Al-Kawaz, M. N. N., Etchill, E., Giuliano, K., Dong, J., Bush, E., Kim, B., Choi, C., Whitman, G., Cho, S. 2022; 68 (12): 1501-1507

  Abstract

  Acute brain injury (ABI) occurs frequently in patients receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO). We examined the association between peri-cannulation arterial carbon dioxide tension (PaCO 2 ) and ABI with granular blood gas data. We retrospectively analyzed adult patients who underwent VA-ECMO at a tertiary care center with standardized neuromonitoring. Pre- and post-cannulation PaCO 2 were defined as the mean of all PaCO 2 values in the 12 hours before and after cannulation, respectively. Peri-cannulation PaCO 2 drop (∆PaCO 2 ) equaled pre- minus post-cannulation PaCO 2 . ABI included intracranial hemorrhage (ICH), ischemic stroke, hypoxic-ischemic brain injury, cerebral edema, seizure, and brain death. Univariable logistic regression analysis was performed for the presence of ABI. Out of 129 VA-ECMO patients (median age = 60, 63% male), 43 (33%) patients experienced ABI. Patients had a median of 11 (interquartile range: 8-14) peri-cannulation PaCO 2 values. Comparing patients with and without ABI, pre-cannulation (39 vs. 42 mm Hg; p = 0.38) and post-cannulation (37 vs. 36 mm Hg; p = 0.82) PaCO 2 were not different. However, higher pre-cannulation PaCO 2 (odds ratio [OR] = 2.10; 95% confidence interval [CI] = 1.10-4.00; p = 0.02) and larger ∆PaCO 2 (OR = 2.69; 95% CI = 1.18-6.13; p = 0.02) were associated with ICH. In conclusion, in a cohort with granular arterial blood gas (ABG) data and a standardized neuromonitoring protocol, higher pre-cannulation PaCO 2 and larger ∆PaCO 2 were associated with increased prevalence of ICH.

  View details for DOI 10.1097/MAT.0000000000001699

  View details for Web of Science ID 000894502700019

  View details for PubMedID 35671442

  View details for PubMedCentralID PMC9477972

• Long-term survival after heart transplantation for cardiac sarcoidosis JOURNAL OF CARDIAC SURGERY McGoldrick, M. T., Giuliano, K., Etchill, E. W., Barbur, I., Yenokyan, G., Whitman, G., Kilic, A. 2021; 36 (11): 4247-4255

  Abstract

  Cardiac sarcoidosis is an increasingly common indication for a heart transplant, but there is a paucity of knowledge with regard to long-term outcomes following transplant.We utilized the Organ Procurement and Transplantation Network database to retrospectively analyze adult patients undergoing first-time, single-organ heart transplant between January 1999 and March 2020.Of the 41,447 patients that underwent heart transplant during the study period, 289 (0.7%) were transplanted for a primary diagnosis of restrictive cardiomyopathy due to cardiac sarcoidosis (RCM-Sarcoidosis). RCM-Sarcoidosis was associated with 33% reduced risk of mortality over 10 years compared to non-RCM indications in a multivariable Cox proportional hazards model (p = .03). Ten-year survival functions were improved among RCM-Sarcoidosis compared to this reference group (73.4% [64.2%-80.6%] vs. 59.5% [58.8%-60.1%], p = .002). Among patients transplanted after 1999 who had at least 10 years of follow-up (n = 19,489), median survival of RCM-Sarcoidosis patients was 11.9 [8.3-14.6] years while that of non-RCM patients was 9.9 [4.0-13.1] years. RCM-Sarcoidosis was not associated with an increased risk of secondary outcomes such as graft failure, rejection, or infection. The incidence of retransplant was comparable between RCM-Sarcoidosis and non-RCM patients (1.38% vs. 1.50%, p = .93).These data suggest that long-term outcomes following transplant for cardiac sarcoidosis are favorable compared to heart transplant for other indications.

  View details for DOI 10.1111/jocs.15783

  View details for Web of Science ID 000666850500001

  View details for PubMedID 34176168

• High rates of de novo malignancy compromise post-heart transplantation survival JOURNAL OF CARDIAC SURGERY Giuliano, K., Canner, J. K., Etchill, E., Suarez-Pierre, A., Choi, C. W., Higgins, R. S. D., Hsu, S., Sharma, K., Kilic, A. 2021; 36 (4): 1401-1410

  Abstract

  Transplant patients are known to have increased risk of developing de novo malignancies (DNMs). As post-transplant survival increases, DNM represents an obstacle to further improving survival. We sought to examine the incidence, types, and risk factors for post-transplant DNM.We studied adult heart transplant recipients from the Organ Procurement and Transplantation Network database (1987-2018). Kaplan-Meier survival analysis was performed to determine annual probabilities of developing DNM, excluding squamous and basal cell carcinoma. Rates were compared to the general population in the Surveillance, Epidemiology, and End Results database. Cox proportional hazards regression was performed to calculate hazard ratios for risk factors of DNM development, all-cause, and cancer-specific mortality.Over median follow-up of 6.9 years, 18% of the 49,361 patients developed DNM, which correlated with an incidence rate 3.8 times that of the general population. The most common malignancies were lung, post-transplant lymphoproliferative disorder, and prostate. Risk was most increased for female genital, tongue/throat, and renal cancers. Male gender, older age, smoking history, and impaired renal function were risk factors for developing DNM, whereas the use of MMF for immunosuppression was protective. Cigarette use, increasing age, the use of ATG for induction and calcineurin inhibitors for maintenance were risk factors for cancer-specific mortality. The development of a DNM increased the risk of death by 40% (p < .001).Heart transplant patients are at increased risk of malignancy, particularly rare cancers, which significantly increases their risk of death. Strict cancer surveillance and attention to immunosuppression are critical for prolonging post-transplant survival.

  View details for DOI 10.1111/jocs.15416

  View details for Web of Science ID 000616672600001

  View details for PubMedID 33567114

• Children's Heart Assessment Tool for Transplantation (CHAT) Score: A Novel Risk Score Predicts Survival After Pediatric Heart Transplantation WORLD JOURNAL FOR PEDIATRIC AND CONGENITAL HEART SURGERY Fraser, C. D., Grimm, J. C., Zhou, X., Lui, C., Giuliano, K., Suarez-Pierre, A., Crawford, T. C., Magruder, J., Hibino, N., Vricella, L. A. 2019; 10 (3): 296-303

  Abstract

  Given the shortage of donor organs in pediatric heart transplantation (HTx), pretransplant risk stratification may assist in organ allocation and recipient optimization. We sought to construct a scoring system to preoperatively stratify a patient's risk of one-year mortality after HTx.The United Network for Organ Sharing database was queried for pediatric (<18 years) patients undergoing HTx between 2000 and 2016. The population was randomly divided in a 4:1 fashion into derivation and validation cohorts. A multivariable logistic regression model for one-year mortality was constructed within the derivation cohort. Points were then assigned to independent predictors ( P < .05) based on relative odds ratios (ORs). Risk groups were established based on easily applicable, whole-integer score cutoffs.A total of 5,700 patients underwent HTx; one-year mortality was 10.7%. There was a similar distribution of variables between derivation (n = 4,560) and validation (n = 1,140) cohorts. Of the 12 covariates included in the final model, nine were allotted point values. The low-risk (score 0-9), intermediate-risk (10-20), and high-risk (>20) groups had a 5.18%, 10%, and 28% risk of one-year mortality ( P < .001), respectively. Both intermediate-risk (OR = 2.46, 95% confidence interval [95% CI]: 1.93-3.15; P < .001) and high-risk (OR = 9.24, 95% CI: 6.92-12.35; P < .001) scores were associated with an increased risk of one-year mortality when compared to the low-risk group.The Children's Heart Assessment Tool for Transplantation score represents a pediatric-specific, recipient-based system to predict one-year mortality after HTx. Its use could assist providers in identification of patients at highest risk of poor outcomes and may aid in pretransplant optimization of these children.

  View details for DOI 10.1177/2150135119830089

  View details for Web of Science ID 000470668700008

  View details for PubMedID 31084316

• Comparing the long-term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database JOURNAL OF SURGICAL ONCOLOGY Giuliano, K., Ejaz, A., Reames, B. N., Choi, W., Sham, J., Gage, M., Johnston, F. M., Ahuja, N. 2018; 118 (3): 486-492

  Abstract

  Gastrointestinal stromal tumors (GIST) are the most common sarcoma arising from the gastrointestinal tract. Data regrading long-term prognosis based on tumor location (stomach vs small intestine) are mixed, so we aimed to analyze their outcomes using a large national oncology database.The National Cancer Database was queried for cases of stomach and small intestine GIST between the years 2004 and 2014. Survival analysis was performed using the Kaplan-Meier method, and factors related to survival were compared using the Cox proportional hazards model.Of 18 900 total patients, those with small intestine GIST had larger median tumor size (6.2 cm; interquartile range [IQR], 3.8 to 10.0 vs stomach: 5.0 cm; IQR, 3.0 to 9.0; P < 0.001) and a higher incidence of tumors with ≥5 mitoses/50 HPF (29.3% vs stomach: 24.2%; P < 0.001). Unadjusted median overall survival (OS) was longer for patients with stomach GIST (10.3 years) as compared to small intestine GIST (9.4 years) (P = 0.01). After controlling for patient and tumor-related factors, however, OS did not differ between stomach and small intestine GIST (hazard ratio, 1.19; 95% confidence interval, 0.88 to 1.61; P = 0.26).Patients with small intestine GIST more commonly have larger, high mitotic rate tumors, but despite these worse prognostic features, tumor location did not independently impact OS.

  View details for DOI 10.1002/jso.25172

  View details for Web of Science ID 000445733400016

  View details for PubMedID 30129672